PBM
Psyence Biomedical Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.21
P/S
0.00
EV/EBITDA
-5.94
DCF Value
$7.60
FCF Yield
-7781.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.6%
ROA
13.8%
ROIC
-54.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0.00 | $-753.3K | $-0.51 |
| FY 2024 | $0.00 | $1.0M | $1.78 |
| Q2 2024 | $0.00 | $141.5K | $5.50 |
| FY 2023 | $0.00 | $-51.2M | $-7.85 |
Company Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
0.31
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.